Revolution in the fight against glioblastoma: Europe is researching personalized therapies!

Revolution in the fight against glioblastoma: Europe is researching personalized therapies!

A new research project called Percareglio, under the direction of Prof. Dr. Jörg W. Bartsch from the Clinic for Neurosurgery at the University of Marburg, aims to develop personalized therapy approaches for glioblastomas. This aggressive form of brain tumor is known for being difficult to treat and has a medium survival expectation of less than 15 months. The project receives a funding of around 1.3 million euros from the European Union to research innovative approaches to combat this disease.

As part of Percareglio, a detailed molecular analysis of each tumor is carried out, which is similar to a genetic fingerprint. The use of molecular data, artificial intelligence and modern laboratory process for tumor cultivation are intended to identify medication that make the tumors vulnerable. The aim is to develop individual treatments for patients based on the specific biological properties of their tumors.

research approaches and cooperation

The project is not alone, but part of the European initiative ERA Permed, which focuses on promoting personalized medicine. In cooperation with five other research groups from Freiburg, Paris, Coimbra, Barcelona and Bucharest, the molecular heterogeneity of the glioblastomas is examined. The focus is on recognizing differences at the molecular level in order to develop new treatment approaches.

In addition to the molecular analysis, the Perclio project pursues the goal of determining individualized parameters to predict recurrence susceptibility to recurrence and resistance to therapy. This is done by combining multi-omics data from tissue and liquid biopsies with clinical and imaging data. Current monitoring methods are often limited and are mainly based on radiological processes that have a limited sensitivity. Data from the research network should lead to the development of personalized markers and risk models in order to increase the chances of successful treatment.

challenges and future prospects

The glioblastoma not only presents patients with enormous challenges, but also researchers worldwide. Despite numerous clinical studies, there have been no significant breakthroughs in standard therapy in recent years, which includes surgery, chemotherapy and radiation. The average survival remains 14 months, which underlines the urgent need for new therapeutic approaches in order to better understand the origin and heterogeneous properties of the glioblastoma.

With projects such as Percareglio and Percroclio, a new way in the treatment of glioblastomas is sought. The combination of biological knowledge, technologies and clinical research is intended to lead to innovative therapies. These research projects are coordinated by the University of Marburg, while the BMBF supports the measures to support the transfer of innovative research results into clinical practice.

Overall, the development in personalized medicine in glioblastom shows promising approaches that may be able to make the decisive difference in the fight against this aggressive tumor form. The path to a new era of individual cancer treatment is paved by the cooperation of international research teams.

For more information: University of Marburg , BMBF health research href = "https://www.bihealth.org/de/forschung/trg-projekt/personalisen-diagnostik-beim-glioblastom/"> Buhealth .